Pembrolizumab for advanced prostate adenocarcinoma: Findings of the KEYNOTE-028 study

Annals of Oncology

Volumn 29, Issue 8, 2018, Pages 1807-1813

  Hansen, A R ^l   Massard, C ^a   Ott, P A ^b   Haas, N B ^c   Lopez, J S ^d   Ejadi, S ^e   Wallmark, J M ^f   Keam, B ^g   Delord, J P ^h   Aggarwal, R ⁱ   Gould, M ^j   Yang, P ^j   Keefe, S M ^j   Piha Paul, S A ^k  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^e Virginia G Piper Cancer Center   (United States)

^f Associates in Oncology and Hematology ^*  (United States)

^g Seoul National University Hospital   (South Korea)

^h INSTITUT CLAUDIUS REGAUD   (France)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j MERCK RESEARCH LABORATORIES   (United States)

^k UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^l PRINCESS MARGARET HOSPITAL   (Canada)

more..

Author keywords

Castration resistant prostate cancer; PD 1; PD L1; Pembrolizumab

Indexed keywords

PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; TRIACYLGLYCEROL LIPASE; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BODY WEIGHT LOSS; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; DECREASED APPETITE; DIARRHEA; DRUG SAFETY; FATIGUE; HUMAN; HYPERTHYROIDISM; LACK OF DRUG EFFECT; MACULOPAPULAR RASH; MALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION; PRURITUS; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VERY ELDERLY; ADENOCARCINOMA; CLINICAL TRIAL; MIDDLE AGED; MORTALITY; PATHOLOGY; PROSTATE; PROSTATE TUMOR;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; HUMANS; MALE; MIDDLE AGED; NAUSEA; PROGRAMMED CELL DEATH 1 RECEPTOR; PROGRESSION-FREE SURVIVAL; PROSTATE; PROSTATIC NEOPLASMS; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;

EID: 85052338982     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdy232     Document Type: Article

References (34)

1. National Cancer Institute. SEER Stat Facts: Prostate Cancer. https://seer.cancer.gov/statfacts/html/prost.html (28 June 2018, date last accessed).
2. Ferlay J, Soerjomataram I, Dikshit R et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136(5): E359–E386.
3. National Comprehensive Cancer Network I. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Prostate Cancer (Version 3.2018). June 21, 2018. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf (28 June 2018, date last accessed).
4. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12(4): 252–264.
5. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 2010; 236: 219–242.
6. Thoma C. Prostate cancer: PD-L1 expression is common and indicates poor prognosis. Nat Rev Urol 2016; 13(1): 5.
7. Gevensleben H, Dietrich D, Golletz C et al. The immune checkpoint regulator PD-L1 is highly expressed in aggressive primary prostate cancer. Clin Cancer Res 2016; 22(8): 1969–1977.
8. Massari F, Ciccarese C, Calio A et al. Magnitude of PD-1, PD-L1 and T lymphocyte expression on tissue from castration-resistant prostate adenocarcinoma: an exploratory analysis. Targ Oncol 2016; 11(3): 345–351.
9. Haffner MC, Guner G, Taheri D et al. Comprehensive evaluation of programmed death-ligand 1 expression in primary and metastatic prostate cancer. Am J Pathol 2018; 188(6): 1478–1485.
10. Ness N, Andersen S, Khanehkenari MR et al. The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort. Oncotarget 2017; 8(16): 26789–26801.
11. Petitprez F, Fossati N, Vano Y et al. PD-L1 expression and CD8(þ) T-cell infiltrate are associated with clinical progression in patients with node-positive prostate cancer. Eur Urol Focus 2017 Jun 21 [Epub ahead of print], doi: 10.1016/j.euf.2017.05.013.
12. Taube JM, Klein A, Brahmer JR et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014; 20(19): 5064–5074.
13. VR (Pembrolizumab) for Injection, for Intravenous Use. Whitehouse Station, NJ: Merck Sharpe & Dohme Corp., 11/2017.
14. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45(2): 228–247.
15. Romeu JL. Understanding binomial sequential testing. Statistical Confidence, Reliability Information Analysis Center (RIAC START). START 2016; 12: 1–8.
16. Reck M, Rodriguez-Abreu D, Robinson AG et al. Pembrolizumab versus chemotherapy for PD-L1logiestical Confidence, Reliability. N Engl J Med 2016; 375(19): 1823–1833.
17. Bellmunt J, Mullane SA, Werner L et al. Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. Ann Oncol 2015; 26(4): 812–817.
18. Robert C, Schachter J, Long GV et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372(26): 2521–2532.
19. Daud A, Blank CU, Robert C et al. KEYNOTE-006 study of pembrolizumab (pembro) versus ipilimumab (ipi) for advanced melanoma: efficacy by PD-L1 expression and line of therapy. J Clin Oncol 2016; 34(Suppl): 9513.
20. Robert C, Ribas A, Wolchok JD et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014; 384(9948): 1109–1117.
21. Velasco R, Bruna J. Taxane-induced peripheral neurotoxicity. Toxics 2015; 3(2): 152–169.
22. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007; 25: 267–296.
23. Pitt JM, Marabelle A, Eggermont A et al. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. Ann Oncol 2016; 27(8): 1482–1492.
24. Pasero C, Gravis G, Guerin M et al. Inherent and tumor-driven immune tolerance in the prostate microenvironment impairs natural killer cell antitumor activity. Cancer Res 2016; 76(8): 2153–2165.
25. Sfanos KS, Bruno TC, Maris CH et al. Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res 2008; 14(11): 3254–3261.
26. Flavell RA, Sanjabi S, Wrzesinski SH, Licona LP. The polarization of immune cells in the tumour environment by TGFbeta. Nat Rev Immunol 2010; 10(8): 554–567.
27. Lu X, Horner JW, Paul E et al. Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature 2017; 543(7647): 728–732.
28. Kwon ED, Drake CG, Scher HI et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2014; 15(7): 700–712.
29. Beer TM, Kwon ED, Drake CG et al. Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J Clin Oncol 2017; 35(1): 40–47.
30. Graff JN, Alumkal JJ, Drake CG et al. Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer. Oncotarget 2016; 7(33): 52810–52817.
31. Smits M, van der Doelen MJ, Westdorp H et al. Immunological and genomic correlates of response to anti-PD1 checkpoint therapy in mismatch proficient and deficient patients with metastasized castration resistant prostate cancer. J Clin Oncol 2018; 36(Suppl 6): 248–248.
32. Boudadi K, Suzman DL, Luber B et al. Phase 2 biomarker-driven study of ipilimumab plus nivolumab (Ipi/Nivo) for ARV7-positive metastatic castrate-resistant prostate cancer (mCRPC). J Clin Oncol 2017; 35: 5035–5035.
33. Beer TM, Armstrong AJ, Rathkopf D et al. Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study. Eur Urol 2017; 71(2): 151–154.
34. Loriot Y, Fizazi K, de Bono JS et al. Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: outcomes from the randomized controlled phase 3 AFFIRM trial. Cancer 2017; 123(2): 253–262.